Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)
| Autor: | Archana Upadhya, Khushwant S. Yadav, Ambikanandan Misra |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms Pharmaceutical Science 02 engineering and technology Gene delivery 030226 pharmacology & pharmacy 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Pharmacotherapy Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Clinical significance Lung cancer neoplasms Drug Carriers business.industry respiratory system 021001 nanoscience & nanotechnology medicine.disease respiratory tract diseases Clinical trial Liposomes Nanoparticles Non small cell Animal studies Nanocarriers 0210 nano-technology business |
| Zdroj: | Expert Opinion on Drug Delivery. 18:103-118 |
| ISSN: | 1744-7593 1742-5247 |
| DOI: | 10.1080/17425247.2021.1832989 |
| Popis: | Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may provide a suitable alternative to regular formulations to overcome inherent drawbacks and provide better treatment modalities for the patient.The article explores the application of drug loaded nanocarriers for lung cancer treatment. Drug-loaded nanocarriers can be modified to achieve controlled delivery at the desired tumor infested site. The type of nanocarriers employed are diverse based on polymers, liposomes, metals and a combination of two or more different base materials (hybrids). These may be designed for systemic delivery or local delivery to the lung compartment (via inhalation).Nanocarriers can improve pharmacokinetics of the drug payload by improving its delivery to the desired location and can reduce associated systemic toxicities. Through nanocarriers, a wide variety of therapeutics can be administered and targeted to the cancerous site. Some examples of the utilities of nanocarriers are codelivery of drugs, gene delivery, and delivery of other biologics. Overall, the nanocarriers have promising potential in improving therapeutic efficacy of drugs used in NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|